Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...
Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...
Kling Biotherapeutics ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, ...
In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...